<DOC>
	<DOCNO>NCT00003697</DOCNO>
	<brief_summary>RATIONALE : Dimethylxanthenone acetic acid may stop growth cancer cell stop blood flow tumor . PURPOSE : Phase I trial study effectiveness dimethylxanthenone acetic acid treat patient solid tumor respond previous therapy .</brief_summary>
	<brief_title>Dimethylxanthenone Acetic Acid Treating Patients With Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxicity dimethylxanthenone acetic acid ( DMXAA ) patient solid tumor . II . Establish maximum tolerate dose drug patient . III . Determine pharmacokinetics DMXAA patient . IV . Determine effect regimen coagulation parameter , TNF cytokine production , nitric oxide , serotonin production patient . V. Assess efficacy drug patient population . VI . Determine effect drug tumor vasculature evaluate change apparent MRI scan patient . OUTLINE : This dose escalation , multicenter study . Patients receive dimethylxanthenone acetic acid ( DMXAA ) IV 20 minute weekly 6 week , follow 2 week rest . An additional course therapy may administer absence unacceptable toxicity disease progression . Cohorts 3 patient receive escalated dos DMXAA maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 patient experience dose limit toxicity . PROJECTED ACCRUAL : A minimum 3 patient accrue dose level use determine maximum tolerate dose .</detailed_description>
	<mesh_term>Vadimezan</mesh_term>
	<mesh_term>Retinol acetate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm solid tumor amenable standard therapy refractory conventional therapy Tumor mass large 3 cm accessible MRI scan Documented progression within past 2 month PATIENT CHARACTERISTICS : Age : 18 75 Performance status : WHO 02 Life expectancy : Greater 3 month Hematopoietic : Hemoglobin least 9 g/dL WBC least 3,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 1.2 mg/dL ALT le 2 time upper limit normal ( ULN ) Alkaline phosphatase less 2 time ULN Renal : Creatinine le 1.5 mg/dL Other : Fertile patient must use effective contraception No concurrent malignancy except cone biopsied carcinoma situ cervix adequately treat basal squamous cell carcinoma skin No serious medical condition No uncontrolled infection serious infection within past 28 day Must live within 1 hour Mount Vernon Hospital , UK PRIOR CONCURRENT THERAPY : At least 4 week since prior anticancer therapy ( 6 week nitrosoureas mitomycin ) recover</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>